Prescient Therapeutics Ltd. (PTX)
CXA CXA Primary Summary
Prescient Therapeutics Ltd. (PTX) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Prescient Therapeutics Ltd. ever had a stock split?
Prescient Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Steven Lee Yatomi-Clarke CEO | CXA Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Prescient Therapeutics Limited is a forefront clinical stage oncology company based in Melbourne, Australia, dedicated to developing innovative treatments for a variety of cancers. The company's focus is on creating novel drug candidates with the potential to significantly improve outcomes for patients facing this challenging disease. Originally established in 1986 under the name Virax Holdings Limited, it underwent a rebranding in December 2014 to become Prescient Therapeutics Limited. This rebranding reflects its evolved focus on pioneering cancer treatments. Prescient Therapeutics is recognized for its strategic collaboration with The University of Texas MD Anderson Cancer Center, aimed at developing an innovative blood cancer binder for OmniCAR, highlighting its commitment to leveraging partnerships to advance cancer care.
Products and Services
-
PTX-200:
This is a leading drug candidate developed by Prescient Therapeutics, currently undergoing rigorous clinical trials. PTX-200 is a unique therapy targeting HER2-negative breast cancer, wherein it is in a Phase 2a clinical trial. The innovative approach of PTX-200 also extends to its application in relapsed and refractory Acute Myeloid Leukemia (AML), where it is in a Phase IB/2 clinical trial. Additionally, PTX-200 is being evaluated in a Phase 1b trial for its efficacy against recurrent or persistent platinum-resistant ovarian cancer. This versatility showcases Prescient Therapeutics' commitment to addressing a broad range of challenging cancers through targeted treatments.
-
PTX-100:
PTX-100 represents another promising direction in Prescient Therapeutics’ portfolio, acting as a RhoA inhibitor. It is particularly focused on treating hematological malignancies and solid tumors, especially those characterized by Ras and RhoA mutations. The development of PTX-100 highlights the company's investment in targeting genetic mutations that contribute to cancer progression, underscoring a precision medicine approach towards oncology.
